Downexpression of miRs was associated with tumor development, progression, and metastasis. This study explored the levels of miR-125b in patients with and to assess its diagnostic value and monitor treatment responses for patients with . A total of 379 individuals were recruited and assigned into the study groups. RT-qPCR analysis was performed to conﬁrm the association of miR-125b levels with tumor stages and treatment responses. The median levels of miR-125b in patients with EOC were signiﬁcantly lower than that other controls (P < 0.0001). miR-125b in patients with high FIGO stage (III+IV), lymph node metastasis and chemoresistance were lower than that in patients with early-stage (stage I+II; P < 0.001), without lymph metastasis (p= 0.032) and chemosensitivity (P< 0.001). Low levels of miR-125b had a poor prognosis in patiens with . Using a median value of 0.748 to separate EOC from other controls, the sensitivity and speciﬁcity reached 0.76 (95% CI 0.75 to 0.85) 0.416 (95% CI 0.26 to 0.55), respectively. miR-125b showed a statistically signiﬁcant difference between preoperative and postoperative patients in surgical patient groups (P = 0.003). miR-125b levels was lower in patients with chemoresistance that that in patients with chemosensitivity (P< 0.0001). Serum miR-125b in combination with serum CA125 improved both sensitivity and speciﬁcity in diagnosis of EOC (P< 0.001). This study demonstrated that miR-125b levels were a useful diagnostic biomarker and biomarker to predict the responses to chemotherapy in patients with EOC.
Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease(GVHD).
January 24, 2020
Association of hospital characteristics with outcomes for pediatric neurosurgical accidental trauma patients.
April 8, 2021
National trends and disparities in healthcare access and coverage among adults with asthma and COPD: 1997 – 2018.
January 28, 2021
- ASCO – Lung CancerASCO.20 Virtual Scientific Program, held May 29 - 31, brought professionals from all over the world together to hear the brightest minds in oncology present state-of-the-art treatment modalities and new therapies.
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ASCO 2019The 2019 ASCO Annual Meeting, taking place May 31-June 4 in Chicago, will bring together more than 32,000 oncology professionals from across the globe. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient.